Journal of translational medicine · 2026
CA9 targets ITGB1 to accelerate the progression of colorectal cancer by promoting the neutrophil extracellular traps formation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jie, Li Ben, Zhou Jiajie, Li Ruiqi, Sun Longhe, Xu Zijie, Zhao Shuai, Cheng Yifan, Tian Zhen, Fu Yayan, Zhang Chenkai, Fang Dengyang, Sun Qiannan, Wang Daorong
Аннотация
BACKGROUND: The immunological role of carbonic anhydrase IX (CA9) in colorectal cancer (CRC) progression remains undefined. This study reveals a CA9-driven mechanism promoting tumor progression through neutrophil extracellular traps (NETs).
METHODS: CA9 was identified as a candidate oncogene in CRC through public single-cell RNA sequencing data screening. Endogenous modulation of CA9 in vitro and in vivo was performed to elucidate its function. Flow cytometry and immunofluorescence assays were employed to assess how CA9 promotes neutrophil infiltration and NETs formation in tumor tissues. Finally, molecular docking, co-immunoprecipitation, and cytokine arrays were integrated to investigate the specific mechanisms of CA9-driven CRC progression.
RESULTS: Serum CA9 expression level in CRC patients exhibited significantly elevated relative to controls, correlating with poor clinical prognosis (P < 0.05). Interestingly, CA9 mainly played a significant pro-tumor role in CRC mouse models, promoting tumor progression by regulating neutrophil recruitment and NETs formation. Mechanistically, CA9 binds to ITGB1, activating the NF-κB pathway and triggering increased secretion of C-X-C motif chemokine ligand 8 (CXCL8), which subsequently promoted neutrophil recruitment and NETs formation. Thus, the CA9-ITGB1-CXCL8 axis induces neutrophil reactive oxygen species production and NETs formation, thereby promoting CRC tumor progression.
CONCLUSION: The CA9-driven ITGB1-CXCL8-NETs signaling axis significantly promotes CRC progression, thereby establishing CA9 as a novel potential therapeutic target for CRC.
METHODS: CA9 was identified as a candidate oncogene in CRC through public single-cell RNA sequencing data screening. Endogenous modulation of CA9 in vitro and in vivo was performed to elucidate its function. Flow cytometry and immunofluorescence assays were employed to assess how CA9 promotes neutrophil infiltration and NETs formation in tumor tissues. Finally, molecular docking, co-immunoprecipitation, and cytokine arrays were integrated to investigate the specific mechanisms of CA9-driven CRC progression.
RESULTS: Serum CA9 expression level in CRC patients exhibited significantly elevated relative to controls, correlating with poor clinical prognosis (P < 0.05). Interestingly, CA9 mainly played a significant pro-tumor role in CRC mouse models, promoting tumor progression by regulating neutrophil recruitment and NETs formation. Mechanistically, CA9 binds to ITGB1, activating the NF-κB pathway and triggering increased secretion of C-X-C motif chemokine ligand 8 (CXCL8), which subsequently promoted neutrophil recruitment and NETs formation. Thus, the CA9-ITGB1-CXCL8 axis induces neutrophil reactive oxygen species production and NETs formation, thereby promoting CRC tumor progression.
CONCLUSION: The CA9-driven ITGB1-CXCL8-NETs signaling axis significantly promotes CRC progression, thereby establishing CA9 as a novel potential therapeutic target for CRC.